83_FR_29247 83 FR 29126 - Office of the Director, National Institutes of Health; Notice of Meeting

83 FR 29126 - Office of the Director, National Institutes of Health; Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 121 (June 22, 2018)

Page Range29126-29127
FR Document2018-13419

Federal Register, Volume 83 Issue 121 (Friday, June 22, 2018) 
[Federal Register Volume 83, Number 121 (Friday, June 22, 2018)]
[Notices]
[Pages 29126-29127]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-13419]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Office of AIDS Research Advisory Council.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Office of AIDS Research Advisory Council.
    Date: July 12, 2018.
    Time: 11:00 a.m. to 12:30 p.m.
    Agenda: Report to the OAR Director; Overview of key upcoming OAR 
activities; Updates of the HHS HIV/AIDS Treatment and Prevention 
Guidelines.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Paul A. Sato, Medical Officer, Office of AIDS 
Research, Office of the Director, NIH, 5601 Fishers Lane, Room 2E62 
Rockville, MD 20852, 240-480-2330, paul.sato@nih.gov.

    Any interested participants are encouraged to join this meeting 
at the weblink provided, at least 30 minutes prior to the scheduled 
start time. Information is also available on the Institute's/
Center's home page: www.oar.nih.gov, where an agenda and any 
additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research

[[Page 29127]]

Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome 
Research Loan Repayment Program; 93.187, Undergraduate Scholarship 
Program for Individuals from Disadvantaged Backgrounds, National 
Institutes of Health, HHS)


    Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-13419 Filed 6-21-18; 8:45 am]
 BILLING CODE 4140-01-P

29126 Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices Dated: June 19, 2018. DEPARTMENT OF HEALTH AND Contact Person: Priti Mehrotra, Ph.D., Natasha M. Copeland, HUMAN SERVICES Chief, Immunology Review Branch, Scientific Review Program, Division of Extramural Program Analyst, Office of Federal Advisory Activities, Room #3G40, National Institutes Committee Policy. National Institutes of Health of Health/NIAID, 5601 Fishers Lane, MSC [FR Doc. 2018–13417 Filed 6–21–18; 8:45 am] 9823, Bethesda, MD 20892–7616, 240–669– National Institute of Allergy and BILLING CODE 4140–01–P 5066, pmehrotra@niaid.nih.gov. Infectious Diseases; Notice of Closed Meetings (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, DEPARTMENT OF HEALTH AND Pursuant to section 10(d) of the and Transplantation Research; 93.856, HUMAN SERVICES Federal Advisory Committee Act, as Microbiology and Infectious Diseases amended, notice is hereby given of the Research, National Institutes of Health, HHS) National Institutes of Health following meetings. Dated: June 19, 2018. The meetings will be closed to the Natasha M. Copeland, National Institute of Allergy and public in accordance with the Infectious Diseases; Notice of Closed provisions set forth in sections Program Analyst, Office of Federal Advisory Committee Policy. Meeting 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and [FR Doc. 2018–13414 Filed 6–21–18; 8:45 am] Pursuant to section 10(d) of the the discussions could disclose BILLING CODE 4140–01–P Federal Advisory Committee Act, as confidential trade secrets or commercial amended, notice is hereby given of the property such as patentable material, following meeting. and personal information concerning DEPARTMENT OF HEALTH AND individuals associated with the grant HUMAN SERVICES The meeting will be closed to the public in accordance with the applications, the disclosure of which National Institutes of Health provisions set forth in sections would constitute a clearly unwarranted 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., invasion of personal privacy. Office of the Director, National as amended. The contract proposals and Name of Committee: National Institute of Institutes of Health; Notice of Meeting the discussions could disclose Allergy and Infectious Diseases, Special Pursuant to section 10(a) of the confidential trade secrets or commercial Emphasis Panel, Integrated Preclinical/ Clinical AIDS Vaccine Development Federal Advisory Committee Act, as property such as patentable material, amended (5 U.S.C. App.), notice is Program, (IPCAVD) (U19). and personal information concerning hereby given of a meeting of the Office Date: July 12–13, 2018. individuals associated with the contract Time: 9:00 a.m. to 5:00 p.m. of AIDS Research Advisory Council. proposals, the disclosure of which Agenda: To review and evaluate grant The meeting will be open to the would constitute a clearly unwarranted applications. public, with attendance limited to space invasion of personal privacy. Place: National Institutes of Health, 5601 available. Individuals who plan to Fishers Lane, Rockville, MD 20892 Name of Committee: National Institute of (Telephone Conference Call). attend and need special assistance, such Allergy and Infectious Diseases Special Contact Person: J. Bruce Sundstrom, Ph.D., as sign language interpretation or other Emphasis Panel; Source Selection Meeting Scientific Review Officer, Scientific Review reasonable accommodations, should for NIAID IRF at Fort Detrick. Program, Division of Extramural Activities, notify the Contact Person listed below Date: July 3, 2018. Room 3G11A, National Institutes of Health/ in advance of the meeting. Time: 1:00 p.m. to 3:00 p.m. NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, 240–669–5045, Name of Committee: Office of AIDS Agenda: To review and evaluate contract Research Advisory Council. proposals. sundstromj@niaid.nih.gov. Date: July 12, 2018. Place: National Institutes of Health, 5601 Name of Committee: National Institute of Time: 11:00 a.m. to 12:30 p.m. Fishers Lane, Rockville, MD 20892 Allergy and Infectious Diseases Special Agenda: Report to the OAR Director; (Telephone Conference Call). Emphasis Panel, NIAID Investigator Initiated Overview of key upcoming OAR activities; Program Project Applications (P01). Updates of the HHS HIV/AIDS Treatment Contact Person: Dharmendar Rathore, Date: July 12, 2018. and Prevention Guidelines. Ph.D., Senior Scientific Review Officer, Time: 1:00 p.m. to 6:00 p.m. Scientific Review Program, Division of Place: National Institutes of Health, 5601 Agenda: To review and evaluate grant Extramural Activities, Room 3G30, National Fishers Lane, Bethesda, MD 20892 (Virtual applications. Institutes of Health/NIAID, 5601 Fishers Meeting). Place: National Institutes of Health, 5601 Contact Person: Paul A. Sato, Medical Lane, MSC 9834, Bethesda, MD 20892–9834, Fishers Lane, Rockville, MD 20892 Officer, Office of AIDS Research, Office of the 240–669–5058, rathored@mail.nih.gov. (Telephone Conference Call). Director, NIH, 5601 Fishers Lane, Room 2E62 This notice is being published less than 15 Contact Person: Priti Mehrotra, Ph.D., Rockville, MD 20852, 240–480–2330, Chief, Immunology Review Branch, Scientific days prior to the meeting due to the urgent paul.sato@nih.gov. Review Program, Division of Extramural need to meet timing limitations imposed by Activities, Room #3G40, National Institutes Any interested participants are encouraged the intramural research review cycle. of Health/NIAID, 5601 Fishers Lane, MSC to join this meeting at the weblink provided, (Catalogue of Federal Domestic Assistance 9823, Bethesda, MD 20892–7616, 240–669– at least 30 minutes prior to the scheduled Program Nos. 93.855, Allergy, Immunology, 5066, pmehrotra@niaid.nih.gov. start time. Information is also available on and Transplantation Research; 93.856, Name of Committee: National Institute of the Institute’s/Center’s home page: Allergy and Infectious Diseases Special www.oar.nih.gov, where an agenda and any Microbiology and Infectious Diseases Emphasis Panel, NIAID Investigator Initiated additional information for the meeting will Research, National Institutes of Health, HHS) daltland on DSKBBV9HB2PROD with NOTICES Program Project Applications (P01). be posted when available. Dated: June 19, 2018. Date: July 13, 2018. (Catalogue of Federal Domestic Assistance Natasha M. Copeland, Time: 10:00 a.m. to 5:00 p.m. Program Nos. 93.14, Intramural Research Agenda: To review and evaluate grant Training Award; 93.22, Clinical Research Program Analyst, Office of Federal Advisory applications. Loan Repayment Program for Individuals Committee Policy. Place: National Institutes of Health, 5601 from Disadvantaged Backgrounds; 93.232, [FR Doc. 2018–13415 Filed 6–21–18; 8:45 am] Fishers Lane, Rockville, MD 20892 Loan Repayment Program for Research BILLING CODE 4140–01–P (Telephone Conference Call). Generally; 93.39, Academic Research VerDate Sep<11>2014 17:16 Jun 21, 2018 Jkt 244001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1

Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices 29127 Enhancement Award; 93.936, NIH Acquired (HHS Reference No. E–619–2013–0–US– within fifteen (15) days from the date of Immunodeficiency Syndrome Research Loan 01); this published notice, the National Repayment Program; 93.187, Undergraduate 2. PCT Application No. PCT/US2014/ Institute of Dental and Craniofacial Scholarship Program for Individuals from 058613, filed October 1, 2014 and Research receives written evidence and Disadvantaged Backgrounds, National entitled ‘‘Methods of Modulating Institutes of Health, HHS) argument that establishes that the grant Erythropoiesis with Arginine of the license would not be consistent Dated: June 19, 2018. Vasopressin Receptor 1B Molecules’’ with the requirements of 35 U.S.C. 209 Natasha M. Copeland, (HHS Reference No. E–619–2013–0– and 37 CFR part 404. PCT–02); In response to this Notice, the public Program Analyst, Office of Federal Advisory Committee Policy. 3. U.S. Patent Application No. 15/ may file comments or objections. 022,531, filed March 16, 2016 and Comments and objections, other than [FR Doc. 2018–13419 Filed 6–21–18; 8:45 am] entitled ‘‘Methods of Modulating those in the form of a license BILLING CODE 4140–01–P Erythropoiesis with Arginine application, will not be treated Vasopressin Receptor 1B Molecules’’ confidentially, and may be made (HHS Reference No. E–619–2013–0–US– publicly available. DEPARTMENT OF HEALTH AND 03); License applications submitted in HUMAN SERVICES The patent rights in these inventions response to this Notice will be National Institutes of Health have been assigned and/or exclusively presumed to contain business licensed to the government of the confidential information and any release Prospective Grant of an Exclusive United States of America. of information in these license Patent License: Methods of Modulating The prospective exclusive license applications will be made only as Erythropoiesis With Arginine territory may be the United States and required and upon a request under the Vasopressin Receptor 1B Molecules the field of use may be limited to ‘‘Use Freedom of Information Act, 5 U.S.C. of arginine vasopressin receptor 1B 552. AGENCY: National Institutes of Health, agonists to treat anemia caused by (i) HHS. chronic renal failure on dialysis, (ii) Dated: June 19, 2018. receiving myelosuppressive David W. Bradley, ACTION: Notice. chemotherapy, or (iii) lacking Director, Office of Technology Transfer and SUMMARY: The National Institute of antidiuretic hormone.’’ Innovation Access, National Institute of Dental and Craniofacial Research, an The subject technology is a method of Dental and Craniofacial Research, National using arginine vasopressin receptor 1B Institutes of Health. institute of the National Institutes of Health, Department of Health and (AVPR1B) agonists to increase the [FR Doc. 2018–13443 Filed 6–21–18; 8:45 am] Human Services, is contemplating the number of red blood cells to treat BILLING CODE 4140–01–P grant of an Exclusive Patent License to anemia. The inventors discovered that practice the inventions embodied in the hematopoietic stem cells express Patent Applications listed in the AVPR1B receptor, and these receptors DEPARTMENT OF HEALTH AND Supplementary Information section of play a key role in promoting HUMAN SERVICES this notice to ERYTHRYx Therapeutics, hematopoietic stem and progenitor cell proliferation. The number of red blood National Institutes of Health located in Los Angeles, California. DATES: Only written comments and/or cells and their precursors significantly Government-Owned Inventions; applications for a license which are increased on day 2 following Availability for Licensing received by the Office of Technology vasopressin administration, an onset time much faster than erythropoietin AGENCY: National Institutes of Health, Transfer and Innovation Access, (EPO), which is commonly used to HHS. National Institute of Dental and Craniofacial Research on or before July stimulate red blood cell production for ACTION: Notice. 9, 2018 will be considered. anemia treatment. EPO takes about a week to manifest its clinical effects. The SUMMARY: The invention listed below is ADDRESSES: Requests for copies of the AVPR1B agonists can be used to owned by an agency of the U.S. patent application, inquiries, and jumpstart the hematopoietic system and Government and is available for comments relating to the contemplated erythropoietin can be used to sustain licensing to achieve expeditious an Exclusive Patent License should be the effect. commercialization of results of directed to: Yun Mei, Technology The subject technology is a federally-funded research and Transfer and Patent Specialist, Office of repurposing of an existing drug, development. Foreign patent Technology Transfer and Innovation vasopressin, an AVPR1B agonist, also applications are filed on selected Access, National Institute of Dental and called antidiuretic hormone. It is a nine- inventions to extend market coverage Craniofacial Research, National amino acid peptide secreted from the for companies and may also be available Institutes of Health, BLDG 1 DEM, posterior pituitary and used to treat for licensing. RM667, 6701 Democracy Blvd., patients with central diabetes insipidus, FOR FURTHER INFORMATION CONTACT: Dr. Bethesda, MD 20817; Telephone: (301) an uncommon disorder that causes an Barry Buchbinder, 240–627–3678; 827–4639; Facsimile: (301) 496–1005; imbalance of water in the body. This barry.buchbinder@nih.gov. Licensing Email: yun.mei@nih.gov. imbalance leads to excretion of large information and copies of the U.S. SUPPLEMENTARY INFORMATION: amount of urine (polyuria) and intense patent application listed below may be daltland on DSKBBV9HB2PROD with NOTICES thirst even after drinking fluids obtained by communicating with the Intellectual Property indicated licensing contact at the (polydipsia). 1. U.S. Provisional Patent Application This notice is made in accordance Technology Transfer and Intellectual No. 61/885,258, filed October 1, 2013 with 35 U.S.C. 209 and 37 CFR part 404. Property Office, National Institute of and entitled ‘‘Methods of Modulating The prospective exclusive license will Allergy and Infectious Diseases, 5601 Erythropoiesis with Arginine be royalty bearing, and the prospective Fishers Lane, Rockville, MD 20852; tel. Vasopressin Receptor 1B Molecules’’ exclusive license may be granted unless 301–496–2644. A signed Confidential VerDate Sep<11>2014 17:16 Jun 21, 2018 Jkt 244001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1


Document Created: 2018-11-06 09:50:41
Document Modified: 2018-11-06 09:50:41
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesJuly 12, 2018.
FR Citation83 FR 29126 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR